Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of MRAs on Cardiovascular Disease in Hypertension with Hyperaldosteronemia
NCT05688579Phase 4Enrolling by invitation
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of spironolactone, eplerenone, finerenone in hypertension (HTN), hyperaldosteronism. Started Apr 2023; status: enrolling by invitation.
02
Drugs
spironolactoneeplerenonefinerenone
03
Conditions
hypertension (HTN)hyperaldosteronism
Beyond the preview
Go deeper on NCT05688579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05688579.